计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab175539-100μg |
100μg |
现货 ![]() |
| |
| Ab175539-1mg |
1mg |
现货 ![]() |
| |
| Ab175539-5mg |
5mg |
现货 ![]() |
| |
| Ab175539-10mg |
10mg |
期货 ![]() |
|
| 产品名称 | Fontolizumab (anti-IFNG), 伽马干扰素抑制剂 |
|---|---|
| 别名 | 丰妥珠单抗(抗 IFNG) |
| 英文别名 | IF 1 antibody | IFG antibody | IFI antibody | ifn g antibody | IFN gamma antibody | IFN immune antibody | IFN, immune antibody | IFN-gamma antibody | IFNG antibody | IFNG_HUMAN antibody | Interferon gamma antibody | Immune interferon antibody | Type II In |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | IFNG |
| 种属反应性 | 人(Human) |
| 偶联 | Unconjugated |
| 作用类型 | 抑制剂 |
| 作用机制 | 伽马干扰素抑制剂 |
| 克隆类型 | 重组抗体 |
|---|---|
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 26.3 kDa (Light Chain) & 48.0 kDa (Heavy Chain), under reducing conditions; 195.5 kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 326859-36-3 |
| 分子类型 | 抗体 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
Fontolizumab (anti-IFNG) (Ab175539) - ELISA
Immobilized Recombinant Human IFN-gamma protein (rp156182) at 1.0 μg/mL can bind Fontolizumab (anti-IFNG) (Ab175539) with the EC50 of 23.33 ng/mL.
Fontolizumab (anti-IFNG) (Ab175539) - SEC
The purity of Fontolizumab (anti-IFNG) (Ab175539) is more than 95% verified by HPLC.
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | Ab175539 | |
| 分析证书 | Ab175539 | |
| 分析证书 | Ab175539 |
¥239.90
¥239.90
¥389.90
¥669.90
| 1. Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, Lonovics J, Zákuciová M, D'Haens G, Van Assche G, Ba S et al.. (2006) Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.. Gut, 55 (8): (1131-7). [PMID:16507585] |
| 2. Reinisch W, de Villiers W, Bene L, Simon L, Rácz I, Katz S, Altorjay I, Feagan B, Riff D, Bernstein CN et al.. (2010) Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study.. Inflamm Bowel Dis, 16 (2): (233-42). [PMID:19637334] |
| 3. Baker KF, Isaacs JD. (2018) Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?. Ann Rheum Dis, 77 (2): (175-187). [PMID:28765121] |